U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ciprofloxacin Oral, Injection products
  1. Development Resources

Ciprofloxacin Oral, Injection products

Exceptions or additions to the recognized standards

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Streptococcus pneumoniae

≤1

 2

≥4

≥21

 16-20

≤15

Streptococcus spp. β-
Hemolytic Group

≤1

 2

≥4

≥21

 16-20

≤15

S = Susceptible; I = Intermediate; R = Resistant

For these bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp.

Other Non-Enterobacterales

Neisseria meningitidis

Back to Top